HCA

Business profile & competitive position

HCA Healthcare, Inc. sits in the Healthcare sector under the Medical - Care Facilities industry. At December 31, 2025, it operated 190 hospitals—179 general acute care, seven behavioral, and four rehabilitation hospitals—along with 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers in 19 U.S. states and England. The acute care footprint carried 50,436 licensed beds, while the behavioral hospitals added another 714. Beyond inpatient care, HCA delivers outpatient medical/surgical services, emergency and diagnostic work, mental health treatment, and ancillary care through ASCs, urgent/walk-in clinics, physician practices, home health agencies, hospices, and rehabilitation facilities.

The scale is substantial: 2025 revenues reached $75.6 billion. Yet the margin profile is mid-tier for a capital-heavy service operator. HCA's net margin is 8.8%, which signals a business that can keep costs below reimbursement revenue, but not one with the extremely wide pricing power associated with branded pharmaceuticals or medical devices. The competitive moat here is geographic density and operational scale rather than a single proprietary product. A facility network concentrated in specific markets creates efficiencies in staffing, supply contracts, and payer negotiations. One note on returns: ROE is reported at -112.9%. With net margins positive at 8.8%, that negative return on equity is best read as a low or negative book-equity base—often the footprint left by aggressive capital returns and leverage—rather than a sign that operations are losing money. For a hospital operator, the real competitive test is whether the network can maintain volume, control labor and supply costs, and keep pay rates favorable across its largest states.

Financial posture

HCA currently carries a market capitalization of $94.1B and trades at a price-to-earnings multiple of 14.5. That P/E sits below the level typical of many high-growth healthcare names, which fits the mature, asset-heavy hospital-operator profile. The 8.8% net margin underlines that HCA converts each revenue dollar into modest profit; nothing in the data suggests a transformative margin expansion story, but it does suggest a business with pricing discipline and cost controls in place.

The most striking balance-sheet signal is the -112.9% ROE. Because the company is profitable on an operating basis, a negative ROE of that magnitude usually means shareholder equity on the balance sheet has been pushed below zero through share repurchases, debt-funded capital returns, or accumulated leverage—not through ongoing net losses. At the same time, the beta of 1.11 indicates HCA stock has moved slightly more than the overall market, a reasonable profile for a levered, economically sensitive healthcare services company.

As of the snapshot, the stock price was $434.58, with the 50-day EMA at $417.03 and RSI at 58.5. The EMA/price spread shows the stock trading above its medium-term trend, while the RSI reading sits near neutral territory—neither oversold nor stretched. None of these figures should be read as a directional recommendation; they simply describe where the valuation and trend currently stand.

Strategic priorities & outlook

HCA's most recent SEC 10-K filing outlines four operational priorities. First, the company wants to grow its presence in existing markets, which is consistent with the dense geographic footprint already concentrated in Florida and Texas. Second, it aims for industry-leading performance in clinical, operational, and satisfaction measures—metrics that matter because they affect patient volume, payer contracts, and regulatory scores. Third, HCA emphasizes recruiting and retaining physicians and other healthcare professionals, a particularly relevant goal given the tight labor market for clinical talent. Fourth, the company plans to advance its digital and artificial intelligence capabilities, a theme common across large hospital systems looking to improve scheduling, clinical workflow, and revenue-cycle efficiency.

The 10-K also highlights a heavily concentrated geographic base. HCA draws a large portion of its business from Florida and Texas, which accounted for the bulk of its 2025 revenue mix: 48.9% from managed care and other insurers, and 14.9% from Medicare. That concentration means the strategic outlook is tied not only to national healthcare trends, but also to state-level conditions in those two markets. Growth in existing markets, physician retention, and digital investment are the levers management has identified for defending and extending its position.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, HCA is exposed to the macro and policy currents that shape U.S. healthcare delivery. The most direct channel is government reimbursement. Medicare supplied 14.9% of 2025 revenue, so any change in federal reimbursement rates, site-of-care rules, or Medicare Advantage plan behavior flows straight to the top line. Medicaid policy at the state level is equally important because HCA's footprint is heavily weighted toward Florida and Texas.

Broader labor-market conditions also matter. Hospitals are among the most labor-intensive businesses in the economy, and wage pressure for nurses, technicians, and physicians can compress margins quickly if reimbursement does not keep pace. Supply-chain costs and pharmaceutical pricing affect the cost base as well. More indirectly, HCA is sensitive to public-health conditions, since flu waves, respiratory viruses, or shifts in elective procedure demand alter emergency-room volumes and surgical schedules. Currency is a minor factor relative to domestic peers because operations include England, but the overwhelming majority of activity is U.S.-based. Tariffs and trade policy are less central for a service provider than for medical device or pharmaceutical manufacturers, though imported equipment and supplies still create indirect cost exposure.

Recent developments

The recent headline flow has focused on two related questions: whether HCA can keep squeezing more efficiency from its hospitals, and whether it can sustain earnings growth as the service mix changes. On September 28, 2026, Zacks published "Can Shorter Hospital Stays Help HCA Handle More Patient Demand?" Three days earlier, on September 24, 2026, Zacks also asked "Can HCA Sustain Earnings Growth Despite a Changing Service Mix?" Both pieces point to the same underlying issue: if the company can shorten length-of-stay and shift more care to outpatient settings, it may protect margins in a more cost-conscious reimbursement environment.

Also on September 24, 2026, Defense World ran a "Critical Survey: HCA Healthcare (NYSE:HCA) and Labcorp (NYSE:LH)," providing a peer comparison angle for investors evaluating the two services names. The same day, Pomerantz Law Firm announced an investor alert stating it was investigating claims on behalf of investors of HCA Healthcare, Inc. That headline is worth tracking because regulatory or litigation overhang can raise the discount investors apply to the stock, even if the ultimate outcome is uncertain.

Earnings behavior & post-earnings drift

HCA has compiled an unusual beat streak. Over the last eight reported quarters, the company has beaten earnings estimates every time, for a 100% beat rate, with an average earnings surprise of 6.4%. The average 5-day price move after earnings across those quarters is 1.75%, classified as an upward drift. That pattern suggests the market's real expectation on release day has often fallen below the reported result, leaving a small post-announcement premium.

Looking at the most recent four quarters, the numbers show that beats do not always produce immediate gains. On July 24, 2026, HCA reported actual EPS of $7.59 against an estimate of $7.56, a 0.4% surprise; the stock rose 1.94% the next day and 5.34% over the following five trading days. On April 24, 2026, actual EPS was $7.15 versus $7.12 expected, also a 0.4% surprise, with a 3.09% next-day move but only a 0.15% five-day drift. The January 27, 2026 quarter was more dramatic: actual EPS of $8.01 beat the $7.46 estimate by 7.4%, yet the stock fell 2.89% the next day and 1.31% over the next five sessions. By contrast, the October 24, 2025 report delivered $6.96 against $5.79, a 20.2% surprise, and the stock jumped 4.66% the next day and 2.83% over the following five days.

That variability matters for anyone studying post-earnings drift. The average drift is positive, but individual quarters can diverge sharply, especially when the unofficial consensus differs from the published estimate. The next scheduled report is October 23, 2026, before the market open, with a consensus EPS estimate of $6.7.